demonstrated that MWA can observably increase in interleukin-2 (IL-2) and IFN-γ levels in patients who suffer from non-small cell lung cancer (NSCLC) 1 month after MWA (99). The gene discussed is IL2; the disease is non-small cell lung carcinoma.